DOCSLIB.ORG

FINAL PROGRAMME BHIVA Autumn Conference 12–13 November 2015 QEII Centre London

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FINAL PROGRAMME BHIVA Autumn Conference 12–13 November 2015 QEII Centre London London 2015 QEII Centre FINAL PROGRAMME BHIVA Autumn Conference 12–13 November 2015 QEII Centre London including CHIVA Parallel Sessions Friday 13 November 2015 12 CPD Credits Reference No: 98788 www.bhiva.orgBHIVA Conference Organiser: Mediscript Ltd, 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD T: +44 (0) 20 8369 5380 · F: +44 (0)20 8446 9194 · E: [email protected] CutterguideCutterguide:: N/A PPrintingrinting ProcessProcess:: Offset Size:Size: 210x280+3 mm Pages:Pages: 1 Colors:Colors: C M Y K (4 Color) GDGD:: KC 27496 NatiNativeve FileFile:: Indesign CC WindowsWindows GeneGeneratedrated inin:: Acrobat Distiller 11.0 dolutegradolutegravirv/iabacaviabacavirr /r llamivudineamivudine inner strength THE ONLY SINGLE-PILL REGIMEN BUILTBUILT WWITHITH DOLDOLUTEGRAVIRUTEGRAVIR TheTThhe ttrtreatmenttrreaeatmettmmeennnt eefeffectst feffeecctetscts sseseene seeneenn withiit wthi thddodolutegraviro ldotteelggrurtaegiirrr avwereeerire w cocconsistenteornnses ciissotteennntsit stent acrossacross subgroupssubgroups regardless regardless of o sex,f se x,age, ag erace,, rac ebaseline, baseline viralviral load,load ,background background regimen regimen and a nCD4d C+D TT-cell4-cell count.count . The componentscomponents of o TRIUMEQf TRIUMEQ* wwereere generallygenerally better bette r ttoleratedolerated vs vs Atripla Atrip®la uupp toto 144144 weeks.weeks11-3.-3 BBeforeefore initiatinginitiating treatment treatmen twith wit habacavir-containing abacavir-containin g products,products , HLA-BHLA-B*57015701 ststatusatus mmustust aalwayslways be documented.documented .Abacavir Abacavi rshould should not no bet b usede use ind ipatientsn patien ts knownknown to to carry carry the the HLA-B HLA-*B57015701 aallelellele due due ttoo tthehe ririsksk of hypersensitivityhypersensitivity reaction. reaction. * InIn studiesstudies supportingsupporting TRIUMEQ,TRIUMEQ, DTGDTG 5050 mgmg + ABCABC 600600 mmg/3TCg/3TC 300 300 mgmg were were used. used Bioequivalence. Bioequivalen chase has beenbeen demonstrated.demonstrate1d. VisVisitit wwwww.dolutegravir.comw.dolutegravir.com for for more more information. information. PrescribingPrescribing In Informationformation alopecia,alopecia, ar tharthralgia,ralgia, muscl musclee disor derdisorders,s, asth asthenia,enia, f efever,ver, el eelevationsvations of A ofLT, ALT,AST aASTnd and TriumeqTriumeq ® dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg tablets CPK,CPK, bloo bloodd d ydyscrasias,scrasias, suicid suicidalal ideatio ideationn or suicid or esuicide attemp tattempt,, rhabdom yrhabdomyolysis,olysis, erythemaerythema multi multiforme,forme, Ste Stevens-Johnsonvens-Johnson syndr osyndrome,me, toxic epiderm toxic epidermalal necrolysis necrolysis.. BasicBasic SSeeee S Summaryummary of ofPro Productduct Cha rCharacteristicsacteristics before pbeforerescrib iprescribing.ng. NHSNHS ccosts:osts: 3300 ttablets:ablets: £7 £798.1698.16 EU /EU/1/14/940/001.1/14/940/001. MA h MAolde holder:r: ViiV He ViiValth cHealthcareare UK Ltd, 98 UK0 Ltd, 980 IIndication:ndication: HHIVIV i nin o overver 1 212 ye yearsars an dand ≥ 40 kg. SScreencreen fo forr H LHLA-BA-B *55701701 ppriorrior t oto u suse.e. D oDo no tnot GreatGreat W Westest Ro Road,ad, Bre nBrentford,tford, Midd Middlesexlesex TW8 9 GTW8S. Fu 9GS.rther iFurthernformat informationion is availabl eis f availablerom from uusese ifif H HLA-BLA-B *55701701 ppositive.ositive. Dose:Dose: oonene t abtabletlet o noncece dai ldailyy with with or w iorth owithoutut food. food. Elderly:Elderly: CustomerCustomer C oContactntact Cen Centre,tre, Glax oGlaxoSmithKlineSmithKline UK Ltd ,UK Sto Ltd,ckle yStockley Park Wes tPark, Uxb West,ridge, Uxbridge, LLimitedimited d dataata in in65 65++ yrs yrs.. Creatinine clearance <50 ml/min oorr modemoderate/severerate/severe hepati hepaticc MiddlesexMiddlesex U BUB1111 1B 1BT.T. imimpairment:pairment: NNotot rrecommended.ecommended. Contraindications:Contraindications: HypersensitivityHypersensitivity t oto a nanyy ingingredient.redient. C o-Co-administrationadministration with with dofe tiliddofetilide.e. Warnings/precautions:Warnings/precautions: BBothoth a abacavirbacavir POPOMM andand d dolutegravirolutegravir are are ass oassociatedciated with r iwithsk of riskhyp eofrs ehypersensitivitynsitivity reaction sreactions (HSR). Do n(HSR).ot Do not TTriumeqriumeq i sis a a re registeredgistered tra dtrademarkemark of th eof V itheiV H eViiValth cHealthcareare Group of GroupCompan ofie sCompanies initiateinitiate i nin H HLA-BLA-B *5701+5701+ oorr p previousrevious su suspectedspected aba cabacaviravir HSR. S HSR.top T rStopiume qTriumeq without without delaydelay i fif H HSRSR su suspected.spected. Nev eNeverr reint rreintroduceoduce any do lanyuteg dolutegravir-ravir- or abacav iorr-c abacavir-containingontaining DateDa te ofof approval:a p p rova l: JulyJ uly 20152015 ZincZinc code:c o d e : UK/TRIM/0037/14(3)UK/ TRIM/0037/14(3) productproduct a fafterter su suspectedspected HSR .HSR. Risk sRisks of la coftic lacticacidos iacidosis,s, lipodyst rlipodystrophy,ophy, immune immune Adverse events events should should be be reported. reported. For Forthe theUK, UK,reporting reporting forms forms and information and information can be can be rreactivationeactivation sy ndsyndrome,rome, ost eosteonecrosis.onecrosis. Monit Monitoror LFTs in LFTs Hep ainti tHepatitisis B/C co-i nB/Cfectio co-infection.n. found at at www.mhra.gov.uk/yellowcard. Adverse events events should should also also be be reported reported to to InconclusiveInconclusive da datata on ronela trelationshipionship betw ebetweenen abacav iabacavirr and MI; m andinim iMI;se a lminimisel modiab allle modifiable GlaxoSmithKline onon 0800 0800 221 441. CVCV r irisksk f afactorsctors (e. g(e.g.. smo smoking,king, hype hypertension,rtension, hyperlip hyperlipidaemia).idaemia). Not recom Notmen recommendedded if if dolutegravirdolutegravir re requiredquired b.d b.d.. (wit h(with etrav etravirineirine [witho [withoutut booste boostedd PI], efavi rPI],enz efavirenz,, nevirapine ,nevirapine, Adverse events events should should be be reported. reported. For ForIreland, Ireland, adverse adverse events events should should be reported be reported directly directly rifampicin,rifampicin, b oboostedosted tip tipranavir,ranavir, carb carbamazepine,amazepine, oxcarb aoxcarbazepine,zepine, phenytoin phenytoin,, to thethe HPRA; HPRA; Freepost, Freepost, Pharmacovigilance Pharmacovigilance Section, Section, Health Health Products Products Regulatory Regulatory Authority, Authority, pphenobarbitalhenobarbital an andd St J oSth nJohn’s’s Wort ).Wort). Use w iUseth c lwithadrib cladribineine not reco mnotme recommended.nded. Use with Use with Earlsfort Terrace, Terrace, Dublin Dublin 2, 2, Tel: Tel: +353 +353 1 1676 676 4971, 4971, [email protected] . Adverse events events Mg/Al-containingMg/Al-containing ant antacids,acids, calc iumcalcium,, multiv multivitaminsitamins or iron orre quiironre srequires dosage dosage should alsoalso be be reported reported to to GlaxoSmithKline onon 1800 1800 244 255. separation.separation. Ca Cautionution wit hwith met fmetformin:ormin: moni tmonitoror renal f urenalnctio nfunction and con sandider mconsideretformin metformin dosedose a adjustment.djustment. Ca utioCautionn with with ribaviri ribavirin.n. Pregnancy/lactation:Pregnancy/lactation: NNotot r recommended.ecommended. References:References: 1. 1. TTRIUMEQRIUMEQ S Summaryummary of ofPro Productduct Cha rCharacteristics.acteristics. June 2 0June15. 2015. 2.2. RRaffia F F AvoidAvoid b breast-feeding.reast-feeding. SideSide e effects:ects: SSeeee S SPCPC fo forr de details.tails. Hea Headache,dache, insomn insomnia,ia, sleep/ sleep/ et aal.l. A AIDS.IDS. 22015;015; 229(2):9(2): 1 6167-174.7-174. 3.3. PPappaappa K K et aal.l. PresentedPresented a tat:: 54 54tthh IIntersciencenterscience dreamdream d disorders,isorders, GI GIdis tdisturbance,urbance, fatig ufatigue,e, hypers ehypersensitivity,nsitivity, anorexia anorexia,, depressio ndepression,, CConferenceonference on on An timicAntimicrobialrobial Age nAgentsts and C handemo Chemotherapy;therapy; Septembe Septemberr 5-9, 2014; 5-9, 2014; dizziness,dizziness, s somnolence,omnolence, let hlethargy,argy, mala malaise,ise, cough cough,, nasal sy nasalmptom symptoms,s, rash, prur irash,tus, pruritus, WWashington,ashington, D CDC,, US AUSA.. TRIUMEQ is is a a registe registeredred tradema trademarkrk of the of ViiV the Healthca ViiV Healthcarere group of companies.group of companies. AAtriplatripla is is a a registe registeredred tradema trademarkrk of Bristol-Myers of Bristol-Myers Squibb Squibb & Gilead & S ciences,Gilead LLC. Sciences, LLC. ©2015 ViiV ViiV Healthca Healthcarere group group of companies of companies All rights All reserved. rights reserved. UKUK/TRIM/0022/14(3)/TRIM/0022/14(3) D a Datete of p ofrep preparation:aration: Augus Augustt 2015 2015 UK_TRIM_0022_14(3)_Triumeq_Advert_210x280_Aug2015_GSKDC-PT-UK-2UK_TRIM_0022_14(3)_Triumeq_Advert_210x280_Aug2015_GSKDC-PT-UK-2015-0069_D1.indd015-0069_D1.indd 1 8/14/2015 1:16:54 PM London 2015 QEII Centre INTRODUCTION CONTENTS Programme Summary 4 Sponsors and Exhibitors 15 Programme (BHIVA Autumn) 5–9 Conference Information 16–17 Programme (CHIVA Parallel) 10–11 Exhibition 18 Satellite Symposia and Sponsors’ Workshops 12–13 Speaker Biographies 19–23 BHIVA Committees 14 Dear Colleague elcome to the BHIVA Autumn Conference held at the prestigious QEII Centre in the heart Wof London. I would like to thank Chloe Orkin (Chair of the Conferences Subcommittee), Melinda Tenant- Flowers (Conference
Load more

Recommended publications
  • Dovato, INN-Dolutegravir, Lamivudine
    26 April 2019 EMA/267082/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Dovato International non-proprietary name: dolutegravir / lamivudine Procedure No. EMEA/H/C/004909/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Downloaded from wizmed.com Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features ...............................................................................................
    [Show full text]
  • Second Quarter 2017
    Press release Second quarter 2017 Issued: Wednesday, 26 July 2017, London U.K. GSK delivers further progress in Q2 and sets out new priorities for the Group Q2 sales of £7.3 billion, +12% AER, +3% CER Total loss per share of 3.7p, +59% AER, +29% CER; Adjusted EPS of 27.2p, +12% AER, -2% CER Financial highlights • Pharmaceutical sales, £4.4 billion, +12% AER, +3% CER, Vaccines sales, £1.1 billion, +16% AER, +5% CER, Consumer Healthcare sales, £1.9 billion,+10% AER, flat at CER • Group operating margin 28.5%; Pharmaceuticals 33.6%; Vaccines 33.7%; Consumer 17.7% • Total Q2 loss per share of 3.7p reflecting charges resulting from increases in the valuation of Consumer and HIV businesses and new portfolio choices • Updated 2017 guidance: Adjusted EPS growth now expected to be 3% to 5% CER reflecting impact of Priority Review Voucher • H1 Free Cash Flow £0.4 billion (H1 2016: £0.1 billion) • 19p dividend declared for Q2; continue to expect 80p for FY 2017 Product and pipeline highlights • New product sales of £1.7 billion, +62% AER, +47% CER • HIV two drug regimen (dolutegravir and rilpivirine) filed for approval in US and EU • Shingrix filed for approval in Japan • FDA approval received for subcutaneous Benlysta for treatment of SLE New business priorities to 2020 • New priorities to strengthen innovation, improve performance and build trust • Pharmaceutical R&D pipeline reviewed with target over time to allocate 80% of capital to priority assets in two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation)
    [Show full text]
  • Dovato, INN-Dolutegravir, Lamivudine
    26 April 2019 EMA/267082/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Dovato International non-proprietary name: dolutegravir / lamivudine Procedure No. EMEA/H/C/004909/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 9 2.1.3. Biologic features ...............................................................................................
    [Show full text]
  • Product Monograph for CELSENTRI
    PRODUCT MONOGRAPH PrCELSENTRI maraviroc Tablets 150 and 300 mg CCR5 antagonist ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: July 05, 2019 Submission Control No: 226222 © 2019 ViiV Healthcare group of companies or its licensor. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. Page 1 of 60 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................9 DRUG INTERACTIONS ..................................................................................................19 DOSAGE AND ADMINISTRATION..............................................................................28 OVERDOSAGE ................................................................................................................31 ACTION AND CLINICAL PHARMACOLOGY ............................................................31 STORAGE AND STABILITY..........................................................................................36
    [Show full text]
  • Product Monograph for COMBIVIR
    PRODUCT MONOGRAPH PrCOMBIVIR® lamivudine and zidovudine 150 mg of lamivudine and 300 mg zidovudine tablets Antiretroviral Agent ViiV Healthcare ULC 245 Boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: June 06, 2019 Submission Control No: 226229 © 2019 ViiV Healthcare ULC. All Rights Reserved. COMBIVIR is a registered trademark of the ViiV Healthcare group of companies. Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................15 DOSAGE AND ADMINISTRATION ..............................................................................20 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................23
    [Show full text]
  • Building Innovation, Performance and Trust
    Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
    [Show full text]
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Pristine English Pm Tivicay 25-Jan-2021
    PRODUCT MONOGRAPH PrTIVICAY Dolutegravir tablets Tablets, 10, 25 and 50 mg dolutegravir (as dolutegravir sodium) Dolutegravir dispersible tablets Dispersible tablets, 5 mg dolutegravir (as dolutegravir sodium) Antiretroviral Agent ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: January 25, 2021 Submission Control No: 235583 © 2021 ViiV Healthcare group of companies or its licensor Trademarks are owned by or licensed to the ViiV Healthcare group of companies. Page 1 of 59 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ........................................................................................... 4 WARNINGS AND PRECAUTIONS............................................................................ 4 ADVERSE REACTIONS............................................................................................ 8 DRUG INTERACTIONS .......................................................................................... 16 DOSAGE AND ADMINISTRATION ........................................................................ 21 OVERDOSAGE....................................................................................................... 24 ACTION AND CLINICAL PHARMACOLOGY........................................................
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrTIVICAY Dolutegravir (as dolutegravir sodium) 10, 25 and 50 mg tablets Antiretroviral Agent ViiV Healthcare ULC 245, boulevard Armand-Frappier Laval, Quebec H7V 4A7 Date of Revision: January 31, 2020 Submission Control No: 233258 © 2020 ViiV Healthcare group of companies or its licensor Trademarks are owned by or licensed to the ViiV Healthcare group of companies. Page 1 of 53 TABLE OF CONTENTS PAGE PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ........................................................................................... 4 WARNINGS AND PRECAUTIONS ............................................................................ 4 ADVERSE REACTIONS ............................................................................................ 7 DRUG INTERACTIONS .......................................................................................... 14 DOSAGE AND ADMINISTRATION ........................................................................ 19 OVERDOSAGE ....................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY ......................................................... 22 STORAGE AND STABILITY ..................................................................................
    [Show full text]
  • Thesis Mcamoez.Pdf
    Programa de Doctorat en Biomedicina Línea: Metabolisme, Senyalització Metabòlica i Patologies Associades Facultat de Medicina ‐ Campus de Bellvitge Departament de Patologia i Terapèutica Experimental “Methicillin-resistant Staphylococcus aureus: evolution of endemic clones and emergence of community clones in the hospital environment” Dissertation presented to obtain the Ph.D degree in Biomedicine Supervisor Maria Angeles Domínguez Luzón MD, PhD Professora Asociada de la Universitat de Barcelona Departament de Patologia i Terapèutica Experimental Cap del Servei de Microbiología de l’ Hospital Universitari de Bellvitge Student Mariana Adrião Camoez Barcelona, November 2015 To the memory of my grandfather Raúl Adrião Acknowledgements This thesis was funded by two grants from Fondo de Investigación Sanitaria (grants number PI 07/0944 and PI 10/01783). The PhD student was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III - co-financed by European Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008 and RD12/0015). V Acknowledgements After six years of intensive work and personal efforts, I present my PhD thesis. Working on the Ph.D. has been a wonderful and often overwhelming experience. It has been hard to deal with the real learning experience, how to write papers and proposals, give talks, work in group, collaborate with residents and Master’s students, stay up until the birds start singing, and stay focus... In any case, I am grateful to many people for making the time working on my Ph.D. an unforgettable experience. En primer lugar, quiero agradecer a mi directora de tesis, la Dra.
    [Show full text]
  • Shionogi-Viiv Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor At
    Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 Study Antiviral activity shown by S/GSK1349572 in treatment-experienced subjects resistant to raltegravir from VIKING Study Vienna, Austria, July 22, 2010 – Shionogi-ViiV Healthcare LLC today reported data from two Phase IIb studies showing that its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 (‘572), exhibited potent antiviral activity in treatment-naïve HIV subjects as well as in treatment-experienced subjects resistant to raltegravir (RAL). These clinical results and additional findings on the virologic profile of ‘572 were presented at the XVIII International AIDS Conference in Vienna, Austria. ‘572 is the only once-daily, unboosted integrase inhibitor in Phase IIb clinical development. “There remains a significant need for additional medicines that can help address the complex treatment issues for HIV, and also help simplify treatment regimens for patients. As a once-daily, unboosted integrase inhibitor, ‘572 could provide an important therapy for patients living with HIV,” stated Dr. John Pottage, Chief Scientific and Medical Officer of ViiV Healthcare. “We look forward to confirming the safety and efficacy of this compound in Phase III studies, which are expected to begin by the end of the year.” 1 "We are very pleased with the progress of '572 in collaboration with ViiV Healthcare. We look forward to completing the clinical development process with '572 and providing benefit to the millions of HIV-infected patients throughout the world," said Dr. Tsutae "Den" Nagata, Chief Medical Officer, Shionogi & Co., Ltd.
    [Show full text]
  • Glaxosmithkline Annual Report 2010
    Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
    [Show full text]